Alexander Jung Varond is a lawyer practicing advertising, licensing, intellectual property. Alexander received a B.S. degree from University of California, San Diego in 2006, and has been licensed for 14 years. Alexander practices at Goodwin Procter LLP in San Francisco, CA.
Prior to joining the firm, Mr. Varond served as a Project Engineer, Operations Manager, and Deputy Management Representative to FDA for a medical device firm located in San Diego, California. Mr. Varond also served as a Law Clerk at United States International Trade Commission in the Office of Unfair Import Investigations and as an Intellectual Property Law Clerk at a publicly-traded medical device firm.
Mr. Varond is licensed to practice in California and the District of Columbia.
Articles / Publications
Thomson Reuters Book: Commercialisation of Health Care, November 4, 2013
Trends in Personalized Medicine, October 2013
Blog Posts
Purdue Pharma Petitions FDA to Apply ER/LA Requirements to IR Opioid Analgesics, February 23, 2014
HHS Issues Refill Reminders Guidance Ahead of Compliance Deadline for its HITECH Final Rule, September 25, 2013
HHS to Delay Enforcement and Provide Guidance on HIPAA/HITECH Act Final Rule on the Heels of Adheris Lawsuit , September 12, 2013
Stormy Weather Ahead: Adheris Challenges HHS's Final Rule on HIPAA/HITECH Act, May Provide Further Insight into Supreme Court's Decision in Sorrell, September 10, 2013
Breakthrough Therapy Designation: Stakeholders Discuss the Program One Year Later, June 28, 2013
Fecal Microbiota Transplantation: FDA Announces Limited Enforcement Discretion, July 23, 2013
FDA Provides Insight Into Breakthrough Therapy Designation, Consolidates Guidance for Expedited Programs, July 1, 2013
FDA Releases Revised Draft Guidance for Formal Dispute Resolution: Appeals Above the Division Level, March 15, 2013
OIG Report Calls Into Question Effectiveness of FDA's REMS Program, February 18, 2013
FDA Considering Alternative Approval Pathway, January 15, 2013
FDA Releases Draft Guidance on Enrichment Strategies for Clinical Trials, December 18, 2012
White House Releases Major Paper on Propelling Innovation in Drug Development and Recognizes HP&M's Frank Sasinowski for Contributions, September 27, 2012
IOM Issues Report on Accelerating the Development of New Drugs and Diagnostics: Maximizing the Impact of the Cures Acceleration Network, August 27, 2012
FDA Approves Class-Wide Opioid REMS After More Than Three Years, July 12, 2012
VA Issues Final Rule on Promotion by Pharmaceutical Company Representatives, March 7, 2012 Fellow: and Writing Fellow and was a member of the Moot Court Board and Alternative Dispute Resolution Board. Mr. Varond received a Bachelor of Science degree from University of California, San Diego in 2006 with a double major in Biomedical Engineering and Management Science.
Prior to joining the firm, Mr. Varond served as a Project Engineer, Operations Manager, and Deputy Management Representative to FDA for a medical device firm located in San Diego, California. Mr. Varond also served as a Law Clerk at United States International Trade Commission in the Office of Unfair Import Investigations and as an Intellectual Property Law Clerk at a publicly-traded medical device firm.
Mr. Varond is licensed to practice in California and the District of Columbia.
Articles / Publications
Thomson Reuters Book: Commercialisation of Health Care, November 4, 2013
Trends in Personalized Medicine, October 2013
Blog Posts
Purdue Pharma Petitions FDA to Apply ER/LA Requirements to IR Opioid Analgesics, February 23, 2014
HHS Issues Refill Reminders Guidance Ahead of Compliance Deadline for its HITECH Final Rule, September 25, 2013
HHS to Delay Enforcement and Provide Guidance on HIPAA/HITECH Act Final Rule on the Heels of Adheris Lawsuit, September 12, 2013
Stormy Weather Ahead: Adheris Challenges HHS's Final Rule on HIPAA/HITECH Act, May Provide Further Insight into Supreme Court's Decision in Sorrell, September 10, 2013
Breakthrough Therapy Designation: Stakeholders Discuss the Program One Year Later, June 28, 2013
Fecal Microbiota Transplantation: FDA Announces Limited Enforcement Discretion, July 23, 2013
FDA Provides Insight Into Breakthrough Therapy Designation, Consolidates Guidance for Expedited Programs, July 1, 2013
FDA Releases Revised Draft Guidance for "Formal Dispute Resolution: Appeals Above the Division Level", March 15, 2013
OIG Report Calls Into Question Effectiveness of FDA's REMS Program, February 18, 2013
FDA Considering Alternative Approval Pathway, January 15, 2013
FDA Releases Draft Guidance on Enrichment Strategies for Clinical Trials, December 18, 2012
White House Releases Major Paper on Propelling Innovation in Drug Development and Recognizes HP&M's Frank Sasinowski for Contributions, September 27, 2012
IOM Issues Report on "Accelerating the Development of New Drugs and Diagnostics: Maximizing the Impact of the Cures Acceleration Network", August 27, 2012
FDA Approves Class-Wide Opioid REMS After More Than Three Years, July 12, 2012
VA Issues Final Rule on Promotion by Pharmaceutical Company Representatives, March 7, 2012
Three Embarcadero Center, 28th FloorSan Francisco, CA 94111U.S.A.
Show on mapBy clicking the Submit button, you agree to the Terms of Use, Supplemental Terms and Privacy Policy. You also consent to be contacted at the phone number you provided, including by autodials, text messages and/or pre-recorded calls, from Lawyers.com and its affiliates and from or on behalf of attorneys you request or contact through this site. Consent is not a condition of purchase.
You should not send any sensitive or confidential information through this site. Emails sent through this site do not create an attorney-client relationship and may not be treated as privileged or confidential. The lawyer or law firm you are contacting is not required to, and may choose not to, accept you as a client. The internet is not necessarily secure and emails sent though this site could be intercepted or read by third parties.
This site is protected by reCAPTCHA. See Google’s Privacy Policy and Terms of Service.
